Creatine : Physiology, Evidence, and Clinical Translation

Creatine: The Phosphagen Scaffold of Cellular Energetics and Systems Physiology

Creatine is a nitrogenous organic acid synthesized from arginine, glycine, and methionine, functioning as the central high-energy phosphate buffer in tissues with fluctuating ATP demand. Its phosphorylated form, phosphocreatine, serves as a rapidly mobilizable phosphate reservoir that regenerates ATP from ADP through the creatine kinase reaction, a near-equilibrium enzymatic system that operates orders of magnitude faster than oxidative phosphorylation or glycolysis. This metabolic role, first characterized in skeletal muscle, has now been identified in brain, cardiac muscle, spermatozoa, retina, inner ear, skin, and immune cells. Creatine is not a vitamin, not an essential amino acid, and not a hormone. It is a conditional essentiality: endogenous synthesis from the liver, kidney, and pancreas supplies approximately 1 gram per day, dietary intake from animal flesh supplies another 1 to 2 grams per day in omnivores, and the remaining requirement must be met by these combined sources to maintain a total body pool of approximately 120 to 140 grams in a 70-kilogram adult. The clinical literature on creatine spans four decades, encompasses thousands of studies, and has undergone a conceptual expansion from an ergogenic aid for athletes to a neuroprotective, cardioprotective, and potentially geroprotective molecule. This monograph maps that evolution.

---

Part 1. The Creatine Kinase Circuit: A Bioenergetic Buffer Across All Tissues

The creatine kinase-phosphocreatine system is the most kinetically efficient energy buffer in vertebrate biology. At sites of high and fluctuating ATP demand, the sarcomeric M-line of skeletal muscle, the intercalated disc of cardiac myocytes, the synaptic boutons of neurons, and the flagellum of spermatozoa, the enzyme creatine kinase catalyzes the reversible transfer of a phosphoryl group from phosphocreatine to ADP, yielding ATP and creatine. The reaction is near-equilibrium, meaning its direction is determined solely by the local concentrations of its substrates. When ATP consumption surges, the local ADP concentration rises, and creatine kinase in the forward direction regenerates ATP instantaneously, buffering the ATP/ADP ratio. When ATP demand falls, mitochondrial oxidative phosphorylation restores the ATP pool, and creatine kinase in the reverse direction rephosphorylates creatine, replenishing the phosphocreatine reservoir.

This system confers three distinct bioenergetic advantages. First, phosphocreatine diffuses within the cytosol far more rapidly than ATP, functioning as a spatial energy shuttle that transports high-energy phosphate from the mitochondrial cristae to the sites of ATP utilization, a concept known as the creatine phosphate shuttle. Second, the reaction consumes a proton when operating in the forward direction, providing a localized pH buffer that attenuates the acidification of the cytosol during high-intensity activity. Third, by maintaining a high local ATP/ADP ratio, the system suppresses the activation of AMP-activated protein kinase, a sensor of cellular energy stress that, when chronically activated, promotes catabolic pathways. The creatine kinase system is therefore not merely an emergency backup. It is the primary mechanism by which tissues manage the spatiotemporal mismatch between ATP supply and demand.

1A. The Endogenous Synthesis Gap and Tissue-Specific Creatine Uptake

The endogenous synthesis of creatine is a two-step process that begins in the kidney and pancreas, where arginine and glycine are condensed by L-arginine:glycine amidinotransferase to form guanidinoacetate, and concludes in the liver, where guanidinoacetate is methylated by guanidinoacetate N-methyltransferase using S-adenosylmethionine as the methyl donor. The rate of endogenous synthesis is estimated at approximately 1 gram per day, a figure that is insufficient to meet the total body demand in the absence of dietary intake. The typical omnivorous diet supplies an additional 1 to 2 grams of creatine per day, primarily from red meat and fish. Vegetarians and vegans have negligible dietary creatine intake and rely entirely on endogenous synthesis, which undergoes partial upregulation but frequently fails to achieve the tissue creatine concentrations observed in omnivores. Plasma creatine in vegetarians is lower than in omnivores, and muscle total creatine concentration is typically reduced by 10 to 30 percent. This is not a deficiency state in the classical nutritional sense, but it is a condition of submaximal tissue loading that may have functional consequences under conditions of high metabolic demand.

Tissue uptake of creatine from the circulation is mediated by the sodium- and chloride-dependent creatine transporter, SLC6A8, which concentrates creatine against a large gradient. Skeletal muscle, which contains over 95 percent of the total body creatine pool, expresses the transporter at the sarcolemmal membrane and achieves intracellular total creatine concentrations of 30 to 40 mmol/kg wet weight, with approximately 60 to 70 percent in the phosphorylated form at rest. The brain expresses the creatine transporter at the blood-brain barrier and on neurons and oligodendrocytes, maintaining brain creatine concentrations of 5 to 10 mmol/kg. Cardiac muscle, spermatozoa, photoreceptors, and the cochlear hair cells are additional sites of high creatine transporter expression, each dependent on a continuous supply of creatine from the circulation for optimal function. Genetic deficiency of the creatine transporter, a rare X-linked disorder, produces a severe neurological phenotype characterized by intellectual disability, epilepsy, speech delay, and autistic features, a clinical extreme that illuminates the essential role of creatine in central nervous system function.

1B. A Clinical Taxonomy of Creatine Insufficiency Across Organ Systems

Creatine insufficiency is not a binary diagnosis. It spans a spectrum from a clinically silent, submaximal tissue loading state in vegetarians and older adults, through a functional insufficiency unmasked by high metabolic demand, to a frank deficiency state caused by genetic defects in synthesis or transport.

Dietary Insufficiency and the Vegetarian Phenotype. Vegetarians and vegans have lower plasma and muscle creatine concentrations than omnivores. The functional significance of this reduction has been most studied in two contexts. In cognitive performance, vegetarian subjects randomized to creatine supplementation show improvements in working memory, processing speed, and tasks requiring rapid, repeated cognitive effort, effects that are less pronounced or absent in omnivore subjects, suggesting that the pre-supplementation brain creatine status was rate-limiting for cognitive function. In exercise performance, vegetarian athletes typically show a greater ergogenic response to creatine supplementation than omnivore athletes, consistent with the concept that they begin from a lower baseline tissue creatine concentration and have a larger capacity for loading. This is not a disease state, but it represents a functional reserve that is not fully realized.

Age-Related Decline in Creatine Status. Aging is associated with a progressive decline in muscle creatine and phosphocreatine concentrations, a reduction in the expression and activity of the creatine transporter, and a blunted capacity for endogenous synthesis. The aged muscle has a diminished phosphocreatine resynthesis rate following contraction, a metabolic defect that contributes to the loss of muscle power and fatigue resistance characteristic of sarcopenia. The brain shows a parallel decline: brain creatine concentrations, measured by magnetic resonance spectroscopy, are lower in older adults than in young adults, and lower brain creatine correlates with poorer performance on tests of executive function and processing speed. Whether this age-related decline in tissue creatine is a contributor to the functional losses of aging or simply a biomarker of mitochondrial decline is a central unresolved question.

Pathological Demand Surge and the Failure of Endogenous Compensation. Conditions that acutely increase the metabolic demand on creatine-dependent tissues can overwhelm the capacity of endogenous synthesis. Traumatic brain injury, stroke, and spinal cord injury produce a rapid depletion of brain creatine and phosphocreatine at the injury site, as the creatine kinase system is activated to buffer the ATP decline. In heart failure, myocardial total creatine and phosphocreatine concentrations fall by 30 to 50 percent, and the myocardial phosphocreatine/ATP ratio, measured by phosphorus-31 magnetic resonance spectroscopy, is a strong independent predictor of mortality. In these pathological states, the endogenous synthetic capacity, already operating at or near its maximum, cannot compensate for the sustained drain, creating a functional creatine deficit at the tissue level even in the presence of normal dietary intake.

Genetic Creatine Deficiency Syndromes. Three inborn errors of creatine metabolism are now recognized: deficiency of arginine:glycine amidinotransferase, deficiency of guanidinoacetate N-methyltransferase, and deficiency of the creatine transporter SLC6A8. The first two are autosomal recessive disorders of synthesis; the third is X-linked. All produce a profound depletion of brain creatine, measurable by magnetic resonance spectroscopy, and present with intellectual disability, severe speech and language delay, epilepsy, and movement disorders. The synthetic defects respond to high-dose oral creatine supplementation, with partial amelioration of neurological symptoms, particularly when treatment is initiated early. The transporter defect does not respond to oral creatine, because the transporter is non-functional, and the brain cannot accumulate creatine from the circulation. These syndromes are rare but provide an unequivocal demonstration that brain creatine is essential for normal neurological development and function.

The Organ-Level Consequences of Creatine Insufficiency.

Skeletal Muscle: Power, Fatigue, and Recovery. Skeletal muscle is the tissue in which the creatine kinase system was first described and in which its functional importance is most directly observable. A muscle with a full phosphocreatine pool can sustain maximal force production for approximately 8 to 12 seconds, the duration of a 100-meter sprint, before phosphocreatine depletion forces a decline in power output. Repeated bouts of high-intensity exercise, separated by incomplete recovery intervals, produce a progressive depletion of the phosphocreatine pool that correlates closely with the decline in force production and the accumulation of fatigue. Creatine supplementation, by increasing the pre-exercise phosphocreatine concentration and accelerating its resynthesis during recovery, increases the work output achievable in repeated bouts of high-intensity exercise by 10 to 20 percent, an effect that has been replicated in hundreds of randomized controlled trials. This is the most robust ergogenic effect of any legal nutritional supplement, and it defines creatine's primary clinical application in sports performance, rehabilitation, and the management of sarcopenia.

Brain: Cognition, Neuroprotection, and the Metabolic Hypothesis of Neuropsychiatric Disease. The brain accounts for approximately 20 percent of the body's resting ATP consumption despite representing only 2 percent of its mass. The creatine kinase system is highly expressed in the hippocampus, the frontal cortex, the cerebellum, and the basal ganglia, regions with high and fluctuating metabolic demands. Brain creatine supplementation, typically at doses of 5 to 20 grams per day for periods of weeks to months, increases brain total creatine as measured by magnetic resonance spectroscopy by 5 to 15 percent, with the magnitude of increase dependent on the baseline brain creatine concentration and the duration and dose of supplementation.

The cognitive effects of creatine supplementation are most evident under conditions of metabolic stress. In sleep-deprived subjects, creatine supplementation attenuates the decline in executive function, working memory, and reaction time. In older adults, particularly those with low baseline dietary creatine intake, supplementation improves measures of working memory and processing speed. In traumatic brain injury, oral creatine supplementation has shown trends toward improved cognitive outcomes and reduced post-concussion symptoms, though the trials are small and the results preliminary. In neurodegenerative disease, the rationale for creatine supplementation is strongest for conditions in which impaired energy metabolism is a primary pathogenic driver: Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Large, multicenter trials of creatine in these conditions, however, have been negative for their primary endpoints. The Parkinson's disease trial (NET-PD) and the amyotrophic lateral sclerosis trial both failed to show a significant slowing of disease progression with creatine at doses of 5 to 10 grams per day. The interpretation of these negative results is debated. One view is that brain creatine transport is rate-limited at the blood-brain barrier, and that oral supplementation achieves only modest increases in brain creatine that are insufficient to alter the trajectory of established neurodegeneration. The alternative view is that the trials were conducted in patients with already-advanced disease, and that the window for energetic rescue had closed.

In psychiatry, the creatine literature is nascent but mechanistically intriguing. Depression is associated with reduced brain phosphocreatine and total creatine in some, though not all, magnetic resonance spectroscopy studies. Bipolar disorder and schizophrenia are characterized by mitochondrial dysfunction and oxidative stress, conditions in which the creatine kinase system plays a protective role. Small pilot trials of creatine as an adjunct to standard therapy have shown improvements in depressive symptoms, particularly in women with major depressive disorder, and in bipolar depression when combined with standard mood stabilizers. The evidence is not at a level to support a guideline, but the convergence of a strong mechanistic rationale, a favorable safety profile, and promising pilot data positions neuropsychiatric creatine supplementation as a research priority.

Cardiac Muscle: The Phosphocreatine/ATP Ratio as a Prognostic Marker. The heart is an obligate aerobic organ that cycles between contraction and relaxation approximately 100,000 times per day. The creatine kinase system is essential for the rapid buffering of ATP at the myofibrils and for the transport of high-energy phosphate from the mitochondria to the sites of mechanical work. In heart failure, regardless of etiology, myocardial phosphocreatine falls, and the phosphocreatine/ATP ratio declines. A ratio below 1.6 in human myocardium, measured by phosphorus-31 magnetic resonance spectroscopy, is an independent predictor of cardiovascular mortality, more powerful than ejection fraction or New York Heart Association class. The mechanism is a combination of impaired creatine uptake, reduced creatine kinase activity, and the metabolic remodeling of the failing heart toward a substrate utilization pattern that is less efficient at generating high-energy phosphate.

Oral creatine supplementation in heart failure has been studied in small trials, with mixed results. Some show improvements in ejection fraction, exercise capacity, and quality of life; others show no benefit. The variability likely reflects the heterogeneity of the heart failure population, the inability of oral creatine to robustly increase myocardial creatine concentrations in the setting of impaired transporter expression, and the fact that creatine is a substrate, not a therapy for the underlying myocardial pathology. The concept of myocardial creatine loading as an adjunct in heart failure is mechanistically sound but clinically unproven at a scale that would support a guideline.

Spermatozoa and Male Fertility. The spermatozoon is a cell with an extreme energy demand-to-mitochondrial mass ratio. The flagellum beats at a frequency of 10 to 20 hertz, propelled by dynein ATPases that consume ATP at a rate that challenges the diffusion capacity of the cell. The creatine kinase system is localized to the flagellar midpiece and is essential for the spatial transport of ATP from the mitochondria to the distal flagellum. Creatine transporter expression on the sperm plasma membrane is high, and seminal fluid contains creatine at concentrations that saturate the transporter. Genetic ablation of the creatine kinase gene in mice produces a phenotype of severely impaired sperm motility and male infertility. In human male infertility, seminal plasma creatine concentration and sperm creatine kinase activity correlate positively with sperm motility parameters. The hypothesis that creatine supplementation could improve sperm motility in men with idiopathic asthenozoospermia is mechanistically strong but has not been tested in a randomized controlled trial of sufficient size to support a clinical recommendation.

Bone and the Osteoblast Energetic Demand. Bone remodeling is an energetically expensive process. Osteoblast differentiation and the synthesis of the collagenous bone matrix require a sustained supply of ATP. The creatine kinase system is expressed in osteoblasts, and phosphocreatine supports the high metabolic rate of matrix synthesis. In vitro, creatine supplementation enhances osteoblast differentiation and mineralization. In aging humans, low dietary creatine intake is associated with lower bone mineral density, though the confounders of overall nutritional status and protein intake make a causal inference difficult. A randomized trial of creatine supplementation combined with resistance training in older women showed a modest improvement in bone mineral density at the femoral neck compared to training alone, but the specific contribution of creatine to bone metabolism, independent of its effect on muscle strength and mechanical loading, is not established.

Skin and the Epidermal Energy Barrier. The skin is a metabolically active organ with a rapid rate of cellular turnover. Keratinocytes and fibroblasts express the creatine transporter and the creatine kinase system, and phosphocreatine supports the ATP demand of proliferation and matrix synthesis. Topical creatine formulations have been studied for their capacity to enhance wound healing and to protect against ultraviolet-induced oxidative damage. The evidence is preliminary and limited to small pilot studies. Oral creatine supplementation has been anecdotally associated with improvements in skin hydration and appearance, but no controlled trial has examined dermatological endpoints.

Immune Function and the Bioenergetics of the Activated Lymphocyte. The activated T-lymphocyte undergoes a metabolic switch from oxidative phosphorylation to aerobic glycolysis, a program that supports the biosynthetic demands of clonal expansion. The creatine kinase system is expressed in T-cells, and its activity increases upon activation. Creatine supplementation enhances T-cell proliferation and cytokine production in vitro, and dietary creatine deprivation impairs the immune response in animal models. The concept that creatine status modulates immune competence is plausible but has not been translated into human clinical trials of immune endpoints. The potential for creatine to support immune function in the context of critical illness, aging, or chronic infection is an open area for investigation.

Renal Function and the Creatinine Conundrum. Creatine and phosphocreatine undergo spontaneous, non-enzymatic cyclization to creatinine at a rate of approximately 1.7 percent of the total creatine pool per day. Creatinine is excreted by the kidney and serves as the most widely used clinical biomarker of renal function. The concern that creatine supplementation could impair renal function, either by increasing the nitrogen load or by directly nephrotoxic effects, has been extensively investigated. In individuals with normal renal function, creatine supplementation at doses up to 30 grams per day for periods of up to several years does not produce a detectable decline in glomerular filtration rate, proteinuria, or renal tubular injury markers. The elevation in serum creatinine that accompanies creatine supplementation is a consequence of increased creatinine generation from a larger creatine pool, not a reflection of reduced renal clearance. In patients with pre-existing renal disease, the safety data are less robust, and creatine supplementation is generally avoided due to the theoretical risk of accelerating renal function decline and the confounding effect on the clinical interpretation of serum creatinine. The available small studies in patients with chronic kidney disease, however, have not demonstrated a clear harm signal.

---

Part 2. The Molecular Spectrum of Creatine Action Beyond the Phosphate Bond

The canonical role of creatine as a phosphate buffer has been supplemented, over the past two decades, by a body of work that identifies creatine as a direct modulator of cellular processes that are independent of its role in ATP regeneration.

Mitochondrial Biogenesis and the Creatine-AMPK Axis. Creatine, by maintaining a high local ATP/ADP ratio, suppresses the activation of AMP-activated protein kinase (AMPK), the master sensor of cellular energy stress. Acute creatine supplementation in skeletal muscle reduces AMPK phosphorylation, consistent with an improved cellular energy status. Paradoxically, chronic creatine supplementation, particularly when combined with exercise training, enhances mitochondrial biogenesis, as measured by citrate synthase activity and mitochondrial DNA content. The resolution of this paradox lies in the fact that creatine enables a greater total volume of high-intensity exercise, which is a potent stimulus for mitochondrial biogenesis. The net effect is an increase in both the phosphagen and oxidative capacities of muscle, a dual adaptation that enhances performance across a broader range of exercise intensities.

Myogenic and Neurogenic Gene Expression. Creatine, at concentrations achievable with supplementation, directly modulates the expression of genes involved in muscle and neuronal differentiation. In skeletal muscle satellite cells, creatine increases the expression of myogenic regulatory factors, including myogenin and MRF4, and accelerates the formation of myotubes in vitro. In neural progenitor cells, creatine enhances proliferation and neuronal differentiation, an effect that is blocked by inhibitors of the creatine transporter, indicating that intracellular creatine, not an extracellular signaling event, is the mediator. The mechanism may involve the stabilization of the cellular energy state during the metabolically demanding process of differentiation, or it may involve a direct, non-energetic signaling role of creatine or phosphocreatine that has not been fully characterized.

Methylation Sparing and the One-Carbon Connection. The endogenous synthesis of creatine consumes S-adenosylmethionine in the methylation of guanidinoacetate, a reaction that accounts for approximately 40 to 50 percent of all methyl group transfers in the human body. This is a quantitatively immense demand on the methyl pool. Exogenous creatine supplementation suppresses endogenous synthesis via feedback inhibition of arginine:glycine amidinotransferase, thereby sparing S-adenosylmethionine for other methylation reactions, including DNA methylation, neurotransmitter synthesis, and phosphatidylcholine production. In animal models, creatine supplementation increases the hepatic SAMe/SAH ratio and alters the methylation status of specific genes. The clinical significance of this methylation-sparing effect in humans is not established, but it provides a mechanistic link between creatine status and the broader one-carbon metabolic network that includes methionine, glycine, choline, and the B-vitamins.

Anti-Oxidant and Direct Radical Scavenging. Creatine and phosphocreatine, at millimolar concentrations, directly scavenge reactive oxygen and nitrogen species, including superoxide, peroxynitrite, and hydroxyl radicals. The chemical mechanism involves the formation of creatine-derived radicals that are less reactive and less damaging than the parent species. In mitochondrial preparations, phosphocreatine reduces oxidative damage to mitochondrial DNA and proteins during states of high respiratory activity. In cell culture models of oxidative stress, creatine pre-treatment reduces markers of lipid peroxidation and protein carbonylation. Whether this direct antioxidant effect is physiologically significant at the concentrations achieved in human tissues with oral supplementation is debated. The intracellular concentration of creatine in skeletal muscle, approximately 30 to 40 mmol/kg, is within the range at which direct scavenging has been demonstrated in vitro. In brain, where concentrations are lower (5 to 10 mmol/kg), the antioxidant effect may be more dependent on the creatine kinase system's ability to maintain ATP for glutathione synthesis and NADPH production, an indirect antioxidant mechanism that is energetically mediated.

---

Part 3. The Evidence Mapped by Tissue, Context, and Clinical Endpoint

The creatine literature is among the largest in all of sports nutrition. The challenge is not a lack of data but the need to separate the robustly established effects from the preliminary and the speculative, and to map the evidence to the clinical contexts in which creatine supplementation is a rational intervention.

3.1. Skeletal Muscle Performance and Body Composition: The Ergonomic Core

The effect of creatine supplementation on high-intensity, intermittent exercise performance is a Class IA evidence statement. A Cochrane-level meta-analysis of hundreds of randomized controlled trials confirms that creatine, typically administered as a loading dose of 20 grams per day for 5 to 7 days followed by a maintenance dose of 3 to 5 grams per day, increases maximal strength by approximately 5 to 15 percent, increases power output in repeated sprint or resistance exercise bouts by 10 to 20 percent, and increases lean body mass by 1 to 3 kilograms over 4 to 12 weeks of resistance training. The effect is most pronounced in exercise modalities that rely on the phosphocreatine system: weightlifting, sprinting, jumping, and repeated high-intensity interval efforts. The effect is negligible or absent in endurance exercise at steady state, where ATP demand is met primarily by oxidative phosphorylation and the phosphocreatine system plays a lesser role.

The increase in lean body mass is attributable to both intracellular water retention, which accounts for the initial 1 to 2 kilogram gain within the first week, and an increase in myofibrillar protein synthesis over the longer term, mediated by the greater training volume that creatine enables. The distinction between water and contractile protein is clinically important. The water retention, which is osmotically driven by creatine uptake into the muscle cell, is intramyocellular and contributes to muscle size and mechanical leverage, but it is not pathological edema. The subsequent gain in contractile tissue is training-dependent; creatine without resistance training produces minimal long-term changes in lean body mass beyond the initial osmotic effect.

Responders and Non-Responders. Approximately 20 to 30 percent of individuals show a blunted or absent ergogenic response to creatine. The primary determinants of response are the baseline muscle total creatine concentration and the capacity for its increase with supplementation. Vegetarians, who begin with lower muscle creatine, are more likely to respond robustly. Individuals with a high habitual dietary creatine intake, typically those consuming large quantities of red meat and fish daily, may have muscle creatine concentrations near the ceiling achievable by oral supplementation and show a minimal additional increase. The magnitude of the muscle creatine uptake is also influenced by the co-ingestion of carbohydrate and protein, which stimulate insulin secretion and enhance creatine transporter translocation to the sarcolemma. A practical loading strategy that exploits this synergy is the co-administration of creatine with a carbohydrate-protein beverage, a protocol that increases muscle creatine retention by approximately 20 to 30 percent compared to creatine alone.

3.2. Brain Creatine and Cognitive Function: The Energetic Reserve Hypothesis

The brain, unlike skeletal muscle, is a site at which creatine supplementation faces a pharmacokinetic barrier. The blood-brain barrier expresses the creatine transporter, but the rate of transport is slow, and the brain relies primarily on endogenous synthesis for its creatine supply. Oral creatine supplementation increases brain total creatine by 5 to 15 percent, with the magnitude of increase dependent on the baseline concentration, the dose, and the duration of supplementation. Individuals with low baseline brain creatine, including vegetarians, older adults, and those with genetic defects in creatine synthesis, show the largest increases.

The cognitive benefits of creatine supplementation are most consistently observed under conditions that impose a metabolic stress on the brain. Sleep deprivation, which depletes brain phosphocreatine and reduces cerebral glucose metabolism, is the most studied model. Creatine supplementation at 5 to 20 grams per day attenuates the sleep-deprivation-induced decline in executive function, working memory, reaction time, and mood. In non-sleep-deprived, young, omnivorous adults, the cognitive effects of creatine are small and often non-significant. In older adults, particularly those with low dietary creatine intake, supplementation improves performance on tests of working memory, processing speed, and long-term memory, with effect sizes in the small-to-moderate range. The hypothesis that creatine supports cognitive function by maintaining the cerebral phosphocreatine pool during periods of high demand is consistent with the pattern of effects: benefit is most evident when the system is stressed.

In traumatic brain injury, the creatine depletion at the injury site is profound, and the rationale for supplementation is to support the energetic demands of neuronal repair and to reduce the secondary injury cascade driven by mitochondrial failure. Small trials in children and adults with traumatic brain injury have reported improvements in cognitive outcomes, communication, and functional status with creatine supplementation at doses of 0.4 g/kg/day for periods of 3 to 6 months. The trials are encouraging but underpowered and not replicated at a multicenter level. The safety of long-term, high-dose creatine in the brain-injured population is established, but the efficacy remains an open question.

3.3. Neurodegenerative Disease: The Negative Trials and the Lessons Learned

The failure of creatine to slow disease progression in the large, multicenter trials for Parkinson's disease (NET-PD, over 1,700 patients) and amyotrophic lateral sclerosis is a sobering result that requires interpretation. In Parkinson's disease, the hypothesis was that creatine would support mitochondrial function in dopaminergic neurons, reducing the energetic failure that drives their degeneration. The trial was terminated early for futility after a planned interim analysis showed no separation between creatine (10 grams per day) and placebo. In amyotrophic lateral sclerosis, the hypothesis was similar, targeting the mitochondrial dysfunction in motor neurons. The trial, using 5 to 10 grams per day, was also negative.

Several explanations for these failures have been advanced. First, the blood-brain barrier may limit the increase in brain creatine to levels that are insufficient to alter the trajectory of an already-established neurodegenerative process. Second, the trials enrolled patients with early to moderate disease, but by the time of clinical diagnosis, the underlying neuronal loss may be too advanced for an energetic intervention to rescue. Third, the neurodegenerative disease process may impair the expression or function of the creatine transporter on neurons, rendering them unable to take up the supplemented creatine. Fourth, the dose, while high by ergogenic standards, may be inadequate for the central nervous system, where transport is rate-limited. The lesson is not that creatine is biologically inert in the brain, but that its capacity to modify the course of established neurodegeneration when administered orally at standard doses is likely minimal. The investigation of intranasal or intrathecal creatine delivery, or the development of creatine transporter enhancers, may be required to achieve the brain concentrations necessary for neuroprotection.

3.4. Depression and Bipolar Disorder: The Adjunctive Metabolic Strategy

The role of creatine in the pathophysiology of mood disorders is supported by converging lines of evidence. Magnetic resonance spectroscopy studies, though not universally consistent, have reported reduced brain total creatine and phosphocreatine in the prefrontal cortex and hippocampus of patients with major depressive disorder. The creatine kinase reaction, by buffering ATP and maintaining the mitochondrial membrane potential, supports the neuronal functions that are impaired in depression: neurotransmitter synthesis, synaptic plasticity, and the stress-resilience of hippocampal neurons. Creatine supplementation, by increasing brain phosphocreatine availability, may enhance these functions and augment the response to standard antidepressants.

A 2023 systematic review and meta-analysis identified 7 randomized controlled trials of creatine as an adjunct to standard antidepressant therapy. The pooled analysis showed a significant, moderate antidepressant effect (standardized mean difference approximately 0.4 to 0.6) favoring creatine over placebo, with the effect most pronounced in women. The typical dose was 5 grams per day, and the duration was 8 weeks. The mechanism of the sex-specific effect is not established but may relate to differences in brain creatine concentrations, the expression of the creatine transporter, or the interaction of creatine with estrogen-dependent neuroprotective pathways. The evidence is not yet at a level to support a guideline recommendation, but it is sufficient to position creatine as a rational, low-risk adjunct for patients with major depressive disorder who have had an incomplete response to first-line therapy, particularly women. The combination with a selective serotonin reuptake inhibitor has been studied without significant adverse interactions.

In bipolar disorder, the pilot data are even more preliminary. One small randomized trial of creatine as an adjunct to standard mood stabilizers in bipolar depression showed a significant reduction in depressive symptoms, but the sample size was small, and the result has not been replicated. The theoretical risk that creatine, by enhancing cellular energetics, could trigger a manic switch has not been observed in the limited data available, but it remains a consideration that warrants monitoring in any future trial.

3.5. Sarcopenia and the Aging Muscle: The Synergy with Resistance Training

Sarcopenia, the age-related loss of muscle mass, strength, and function, is a multifactorial process in which impaired energy metabolism is a contributing factor. The aged muscle has a reduced phosphocreatine resynthesis rate, a diminished capacity for high-intensity work, and a blunted anabolic response to protein ingestion and resistance exercise. Creatine supplementation, by increasing the pre-exercise phosphocreatine pool and accelerating its recovery, enables the older adult to perform a greater volume and intensity of resistance training, the primary stimulus for muscle protein synthesis and strength gain.

A meta-analysis of randomized controlled trials in adults over 55 years of age found that creatine supplementation, combined with resistance training, produced a significantly greater increase in lean body mass (approximately 1.4 kilograms additional gain) and maximal strength (approximately 3 to 5 kilograms additional gain on leg press and chest press) compared to resistance training with placebo. The dose used in most trials was 0.1 g/kg/day (approximately 5 to 10 grams per day), without a loading phase. The effect on functional outcomes, such as gait speed and chair-rise time, was smaller and not always statistically significant, suggesting that the translation of strength gains to functional performance requires a task-specific training component that was not included in all trials. Creatine alone, without exercise, does not produce clinically significant gains in muscle mass or function in older adults; it is a permissive agent that enhances the adaptive response to the training stimulus.

3.6. Cardiac Rehabilitation and Heart Failure: The Metabolic Support Rationale

The failing myocardium is creatine-depleted. Oral creatine supplementation in heart failure has been studied in small trials with heterogeneous results. A 2017 systematic review identified 7 randomized trials involving a total of approximately 300 patients with chronic heart failure. The pooled analysis showed a modest improvement in ejection fraction (weighted mean difference approximately 3 to 5 percent) and exercise capacity, but the quality of the individual trials was limited by small sample sizes, short durations, and variability in the dose and formulation of creatine. No trial has examined the effect of creatine on mortality or heart failure hospitalization, the hard endpoints that would be required for a guideline recommendation.

The clinical use of creatine in heart failure is not established, but the mechanistic rationale is strong, and the safety profile is acceptable in patients with stable, compensated heart failure. A reasonable clinical approach, pending definitive data, is to consider creatine at 5 grams per day as an adjunct to standard heart failure therapy in patients who are engaged in a cardiac rehabilitation exercise program, where the ergogenic effect of creatine may enhance the training response and indirectly improve myocardial and peripheral muscle function. Renal function should be monitored, and patients with decompensated heart failure or significant renal impairment should not receive creatine.

---

Part 4. A Clinical Dosing Compendium: Protocols Defined by Tissue Target and Metabolic Context

The optimal creatine dosing strategy is determined by the goal: rapid saturation of tissue stores, gradual accumulation for long-term support, or acute pre-exercise ergogenic effect.

4.1. Evidence-Based Protocols: Dosing Supported by Robust Human Data

Skeletal Muscle Performance: The Classic Loading and Maintenance Protocol. The target is the saturation of skeletal muscle total creatine to its physiological ceiling of approximately 160 mmol/kg dry weight, from a typical baseline of 100 to 120 mmol/kg. The evidence-based protocol is a loading phase of 0.3 g/kg/day of creatine monohydrate for 5 to 7 days, followed by a maintenance dose of 0.03 to 0.05 g/kg/day (approximately 3 to 5 grams per day for a 70-kilogram individual) indefinitely. For a 70-kilogram individual, the loading dose is approximately 21 grams per day, typically divided into four doses of 5 grams each to minimize gastrointestinal discomfort. The loading phase accelerates muscle creatine saturation; without it, the same saturation is achieved with the maintenance dose alone over approximately 4 weeks. The loading phase is not mandatory but is preferred when a rapid ergogenic effect is desired. The maintenance dose is continued for the duration of the training period. On cessation, muscle creatine concentrations return to baseline over 4 to 6 weeks.

Co-ingestion with carbohydrate (approximately 50 to 100 grams) and protein (approximately 20 to 40 grams) increases muscle creatine retention by approximately 20 to 30 percent and is recommended, particularly during the loading phase. Creatine monohydrate is the formulation with the most extensive evidence base for efficacy and safety. Alternative formulations (creatine ethyl ester, creatine hydrochloride, buffered creatine) have not been demonstrated to be superior to monohydrate and are generally more expensive.

Brain Bioenergetic Support: The Gradual Accumulation Protocol. The blood-brain barrier limits the rate of brain creatine uptake. Rapid loading has not been shown to accelerate brain creatine accumulation, and a sustained moderate dose is the preferred strategy. The evidence-based dose for cognitive and neuropsychiatric applications is 5 grams per day, administered without a loading phase, for a minimum of 4 to 8 weeks. Higher doses (10 to 20 grams per day) have been used in traumatic brain injury trials, but the evidence for superiority over 5 grams per day for cognitive outcomes is not established. The duration of supplementation is indefinite if a cognitive or neuropsychiatric benefit is perceived. Co-ingestion with carbohydrate is not required for brain uptake, as the blood-brain barrier creatine transporter is not insulin-sensitive, but it may reduce gastrointestinal discomfort.

Sarcopenia and Aging Muscle: The Exercise-Adjunct Protocol. The target is the enhancement of the adaptive response to resistance training, not the achievement of maximal muscle creatine saturation. The evidence-based dose is 0.1 g/kg/day of creatine monohydrate (approximately 5 to 10 grams per day for a typical older adult), administered without a loading phase, combined with a structured resistance training program of at least two sessions per week. The duration is indefinite, as the benefits are dependent on the continued training stimulus. Creatine without exercise is not indicated for sarcopenia. Adequate total protein intake (1.2 to 1.6 g/kg/day) and vitamin D status are essential co-factors. Renal function should be monitored annually in older adults on long-term creatine.

Genetic Creatine Deficiency Syndromes (AGAT and GAMT Deficiency). The target is the restoration of brain creatine to normal or near-normal levels. In arginine:glycine amidinotransferase deficiency, high-dose oral creatine monohydrate at 0.3 to 0.8 g/kg/day, divided into multiple daily doses, is effective in increasing brain creatine and improving neurological symptoms, particularly when initiated early in life. In guanidinoacetate N-methyltransferase deficiency, creatine supplementation at similar doses is combined with dietary arginine restriction to reduce the accumulation of the neurotoxic intermediate guanidinoacetate. These are specialized metabolic protocols managed by clinical geneticists and metabolic specialists. They are not applicable to the general population.

4.2. Theoretical and Postulated Dosing Frameworks for Future Investigation

Cognitive Aging and Dementia Prevention. Rationale: brain creatine concentrations decline with age, and lower brain creatine correlates with poorer cognitive performance. Postulate: long-term creatine supplementation at 5 grams per day, initiated in midlife (age 50 to 65) in individuals with low dietary creatine intake or vegetarian dietary patterns, may slow the rate of age-related cognitive decline and reduce the risk of mild cognitive impairment or Alzheimer's disease. The primary endpoint would be the change in a global cognitive composite score over 5 to 10 years, with brain creatine measured by magnetic resonance spectroscopy as a surrogate of target engagement. This is a large-scale, long-duration prevention trial that has not been conducted.

Creatine as an Adjunctive Neuroprotective Agent in Traumatic Brain Injury: Timing and Dose Optimization. Rationale: creatine depletion at the injury site is acute and profound. The current oral dosing may be too slow and too low to achieve neuroprotective brain concentrations in the acute post-injury window. Postulate: a protocol of intravenous creatine or high-dose oral creatine (0.4 g/kg/day) initiated within 24 hours of moderate to severe traumatic brain injury and continued for 14 days, combined with standard neurocritical care, may improve cognitive and functional outcomes at 6 months. The primary endpoint is the Glasgow Outcome Scale-Extended. The safety of high-dose creatine in the acute brain-injured patient, with regard to intracranial pressure and renal function, must be established in a Phase I trial before efficacy testing.

Creatine for the Prevention of Post-Partum Depression. Rationale: pregnancy and lactation impose a significant drain on maternal creatine stores, as creatine is actively transported across the placenta and secreted in breast milk. The postpartum creatine depletion may contribute to the energetic deficit in the maternal brain that underlies postpartum depression. Postulate: creatine supplementation at 5 grams per day during the third trimester and the first 6 months postpartum may reduce the incidence and severity of postpartum depressive symptoms. The primary endpoint is the Edinburgh Postnatal Depression Scale score at 6 weeks and 6 months postpartum. The safety of creatine in pregnancy has not been established in large trials, though the limited available data do not indicate teratogenicity. A Phase I safety study in pregnant women is required before an efficacy trial.

Creatine and Glucose Tolerance in Type 2 Diabetes. Rationale: creatine supplementation, by enhancing muscle phosphocreatine stores, may increase the capacity for exercise, which is a cornerstone of diabetes management. A direct effect of creatine on insulin-stimulated glucose uptake, mediated by the osmotic effect of creatine on muscle cell volume or by the AMPK-dependent enhancement of GLUT4 translocation, is plausible but unproven. Postulate: creatine supplementation at 5 grams per day, combined with a structured exercise program, improves HbA1c and insulin sensitivity in individuals with type 2 diabetes compared to exercise with placebo. The primary endpoint is the change in HbA1c at 6 months. The safety of creatine in diabetes, with regard to renal function, must be carefully monitored given the elevated baseline risk of diabetic nephropathy.

Topical Creatine for Skin Aging and Wound Healing. Rationale: skin creatine supports keratinocyte and fibroblast energetics. Systemic creatine supplementation may not achieve high cutaneous concentrations. Postulate: a topical formulation of creatine monohydrate (2 to 5 percent), applied daily, may improve skin hydration, elasticity, and wound healing in aged or photoaged skin. The primary endpoint is the change in skin barrier function and collagen density by biopsy and imaging. This is a dermatological, not a nutritional, application and would require formulation and safety testing specific to the topical route.

4.3. Universal Principles Governing Creatine Dosing

Monohydrate is the Gold Standard. Creatine monohydrate is the formulation for which the vast majority of efficacy and safety data exist. It is chemically stable, well-absorbed, and inexpensive. Alternative formulations have not demonstrated superior efficacy in independent, head-to-head trials and should not be preferred over monohydrate unless a specific, documented intolerance exists.

Saturation is a Ceiling, Not an Escalating Target. The total creatine pool in skeletal muscle has a physiological maximum that cannot be exceeded by increasing the dose. Once muscle creatine saturation is achieved, the excess creatine is excreted in the urine as creatinine. Supraphysiological dosing (greater than 0.3 g/kg/day) beyond the loading phase is wasteful and increases the risk of gastrointestinal side effects without additional tissue loading.

The Osmotic Effect is a Mechanism, Not a Side Effect. The increase in intracellular water that accompanies creatine uptake is a direct consequence of creatine's osmotic activity and is responsible for the initial increase in muscle mass and cell volume. This water is intramyocellular, contributes to muscle function, and is not a cosmetic or pathological concern. Weight gain of 1 to 2 kilograms in the first week is expected and should be communicated to the patient in advance.

Renal Safety is Established in the Absence of Pre-Existing Disease. In individuals with normal renal function, creatine supplementation at standard doses for periods of years does not impair glomerular filtration rate or produce renal tubular injury. The elevation of serum creatinine is a pharmacokinetic artifact, not a nephrotoxic effect. In patients with chronic kidney disease, the safety data are insufficient, and creatine should be avoided unless the indication is compelling and renal function is closely monitored.

Creatine is a Performer, Not a Standalone Anabolic Agent. Creatine enhances the adaptive response to high-intensity exercise. It does not produce significant gains in muscle mass, strength, or cognitive function without the concomitant stimulus of training, sleep, and adequate nutrition. The clinical application of creatine must be embedded within a program of exercise and lifestyle optimization.

---

Part 5. The Unresolved Frontier

The Creatine Transporter as a Rate-Limiting Barrier in Neurological Disease. The failure of oral creatine to alter the course of Parkinson's disease and amyotrophic lateral sclerosis has redirected attention to the blood-brain barrier creatine transporter as the limiting factor. The development of strategies to enhance transporter expression or activity, or to bypass the transporter entirely via intranasal delivery, nanoparticles, or creatine analogs with higher blood-brain barrier permeability, is a frontier of neurotherapeutics. The concept that brain creatine is essential for neuroprotection is not in doubt; the challenge is delivery.

Creatine and Epigenetic Regulation Through Methylation Sparing. The sparing of S-adenosylmethionine by exogenous creatine is a quantitatively significant effect that may have consequences for the epigenome that are not yet explored. The hypothesis that creatine supplementation in pregnancy or early life could alter the developmental epigenome, for better or worse, is important and unstudied. The corollary is that chronic, high-dose creatine in adults could influence the methylation of tumor suppressor genes or aging-related loci, with uncertain long-term consequences.

The Creatine-Microbiome Axis. Creatine that is not absorbed in the small intestine reaches the colon, where it is metabolized by the gut microbiota to creatinine and methylamine, among other products. The interaction between dietary creatine intake, the gut microbiome, and systemic metabolites is almost entirely uncharacterized. The possibility that the ergogenic or cognitive effects of creatine are mediated in part by microbial metabolites is speculative but mechanistically plausible.

Creatine as a Geroprotective Nutrient. The age-related decline in tissue creatine, the ergogenic and potential cognitive benefits of supplementation in older adults, and the methylation-sparing effect collectively raise the question of whether long-term, moderate-dose creatine is a geroprotective intervention. A trial with a composite primary endpoint of physical function, cognitive function, and epigenetic aging clocks in midlife adults followed for a decade would be required to address this question. The feasibility and cost of such a trial are formidable, but the biological rationale is strong enough to warrant consideration.

---

Part 6. Synthesis for an Evidence-Based Approach

Creatine is the most extensively validated ergogenic supplement in the history of sports nutrition, and its biological role extends far beyond the gymnasium floor. It is the primary high-energy phosphate buffer in every tissue with a fluctuating ATP demand, a function that positions it as a conditional essentiality for the brain, the heart, the spermatozoon, and the aging muscle. The evidence for its efficacy in enhancing high-intensity exercise performance and in augmenting the gains from resistance training is definitive. The evidence for cognitive benefit is most robust under conditions of metabolic stress, including sleep deprivation, aging, and vegetarian dietary patterns. The evidence for neuroprotection in established neurodegenerative disease is negative, a finding that likely reflects the pharmacokinetic barrier of the blood-brain creatine transporter rather than a failure of the underlying biology.

The clinical application of creatine is governed by a small set of principles: monohydrate is the formulation of choice, a loading phase is optional for muscle but not for brain, a maintenance dose of 3 to 5 grams per day is sufficient for most long-term indications, and the benefits are dependent on the concomitant presence of a metabolic or mechanical stimulus. Creatine is not a replacement for exercise, sleep, or adequate nutrition. It is a molecule that expands the energetic reserve, enabling the organism to work harder, recover faster, and maintain function under conditions that would otherwise deplete the phosphagen pool.

The future of creatine research lies not in further confirmation of its ergogenic effect, which is settled, but in the exploration of its role in the brain, the aging process, and the interface between energy metabolism and the epigenome. The creatine transporter, long taken for granted as a passive conduit, is emerging as the gatekeeper that determines whether oral creatine can fulfill its therapeutic promise beyond skeletal muscle. The resolution of that pharmacokinetic challenge will determine whether creatine transitions from a supplement for athletes to a therapeutic agent for the aging brain and the failing heart.